Biomedical Translational Research (eBook)

This book, which is the third volume of Biomedical translational research, focuses on the fundamental role of biomedical research in developing new medicinal products. It emphasizes the importance of understanding biological and pathophysiological mechanisms underlying the disease to discover and develop new biological agents. The book uniquely explores the genomic computational integrative approach for drug repositioning. Further, it discusses the health benefits of nutraceuticals and their application in human diseases.  Further, the book comprehensively reviews different computational approaches that employ GWAS data to guide drug repositioning. Finally, it summarizes the major challenges in drug development and the strategies for the rational design of the next generation more effective but less toxic therapeutic agents.

Professor Ranbir Chander Sobti is an Emeritus Professor and Indian National Science Academy (INSA) senior scientist at Punjab University. He is a former Vice-Chancellor of the Panjab University, Chandigarh & Babasaheb Bhimrao Ambedkar University (Central University), Lucknow. He started his career as a cytogeneticist and then moved on to molecular biology, including genomics, to understand the susceptibility and disease process of cancer, COPD, AIDS metabolic syndrome, and kidney diseases. He has also used stem cells and nanoparticles to understand the process of tissue organ development through a designed de-cellularization protocol.  He has published more than 300 research articles in the journals of international repute and has also published more than 40 books.

He is a Fellow of the Third World Academy of Sciences, National Academy of Sciences India, Indian National Science Academy, National Academy of Medical Sciences, National Academy of Agricultural Sciences, Canadian Academy of Cardiovascular Diseases and few others. He was the General President of the Indian Science Congress for the 102nd session held at the University of Jammu in 2013. Dr. Sobti is the recipient of many prestigious awards like the INSA Young Scientist Medal, UGC Career Award, Punjab Rattan Award, JC Bose Oration and Sriram Oration Awards and of Life Time Achievement Awards of the Punjab Academy of Sciences, Zoological Society of India, and the Environment Academy of India.

Dr. Naranjan S. Dhalla is a principal Investigator Experimental Cardiology, Institute of Cardiovascular Sciences Distinguished Professor, Max Rady College of Medicine Professor of Physiology and Pathophysiology, University of Manitoba Senior Fellow, Centre for the Advancement of Medicine Dr. Naranjan S. Dhalla has received more than 170 honours and awards from all over the world. These include the Order of Canada, Order of Manitoba, Order of the Buffalo Hunt from the Province of Manitoba, Fellowship in the Royal Society of Canada, Medal of Honour of the Canadian Medical Association, Research Achievement Award of the Canadian Cardiovascular Society, Chair in Cardiovascular Research and Honorary Professorship at different Universities.

Dr. Dhalla was elected 2nd Greatest Manitoban of All Time and was featured in 'Greatest Manitobans', a book published by the Winnipeg Free Press. Dr Dhalla has published large number of research papers and book Chapters. He has travelled widely and has addressed various national and international conferences.

---

This book, which is the third volume of Biomedical translational research, focuses on the fundamental role of biomedical research in developing new medicinal products. It emphasizes the importance of understanding biological and pathophysiological mechanisms underlying the disease to discover and develop new biological agents. The book uniquely explores the genomic computational integrative approach for drug repositioning. Further, it discusses the health benefits of nutraceuticals and their application in human diseases.  Further, the book comprehensively reviews different computational approaches that employ GWAS data to guide drug repositioning. Finally, it summarizes the major challenges in drug development and the strategies for the rational design of the next generation more effective but less toxic therapeutic agents.